全文获取类型
收费全文 | 11595篇 |
免费 | 1244篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 412篇 |
妇产科学 | 226篇 |
基础医学 | 1517篇 |
口腔科学 | 224篇 |
临床医学 | 1450篇 |
内科学 | 2269篇 |
皮肤病学 | 124篇 |
神经病学 | 1117篇 |
特种医学 | 473篇 |
外科学 | 1356篇 |
综合类 | 732篇 |
一般理论 | 13篇 |
预防医学 | 1149篇 |
眼科学 | 339篇 |
药学 | 725篇 |
中国医学 | 4篇 |
肿瘤学 | 635篇 |
出版年
2022年 | 83篇 |
2021年 | 219篇 |
2020年 | 136篇 |
2019年 | 184篇 |
2018年 | 288篇 |
2017年 | 171篇 |
2016年 | 174篇 |
2015年 | 167篇 |
2014年 | 269篇 |
2013年 | 460篇 |
2012年 | 501篇 |
2011年 | 504篇 |
2010年 | 345篇 |
2009年 | 298篇 |
2008年 | 475篇 |
2007年 | 529篇 |
2006年 | 543篇 |
2005年 | 527篇 |
2004年 | 476篇 |
2003年 | 445篇 |
2002年 | 438篇 |
2001年 | 421篇 |
2000年 | 411篇 |
1999年 | 383篇 |
1998年 | 164篇 |
1997年 | 151篇 |
1996年 | 187篇 |
1995年 | 156篇 |
1994年 | 115篇 |
1993年 | 151篇 |
1992年 | 279篇 |
1991年 | 270篇 |
1990年 | 289篇 |
1989年 | 239篇 |
1988年 | 215篇 |
1987年 | 247篇 |
1986年 | 202篇 |
1985年 | 156篇 |
1984年 | 156篇 |
1983年 | 133篇 |
1982年 | 113篇 |
1981年 | 67篇 |
1980年 | 71篇 |
1979年 | 109篇 |
1978年 | 97篇 |
1977年 | 88篇 |
1976年 | 72篇 |
1975年 | 77篇 |
1973年 | 56篇 |
1970年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 640 毫秒
21.
Melanie Inkster Alan Montgomery Peter Donnan Tom MacDonald Frank Sullivan Tom Fahey 《The British journal of general practice》2005,55(521):931-937
BACKGROUND: Studies show that 60-75% of treated patients with hypertension in general practice, still do not reach the recommended blood pressure targets of <150/90 mmHg. AIM: To investigate aspects of hypertension management in relation to sociodemographic variables, antihypertensive drug treatment, and organisational factors in primary care. DESIGN OF STUDY: Observational study over 3 years. SETTING: Eight general practices in Tayside, UK. METHOD: Participants were 560 randomly selected patients aged 40-79 years receiving treatment for hypertension. The outcome measurement was blood pressure control, expressed in binary form based on the British Hypertension Society audit standard of <150/90 mmHg. RESULTS: Of 536 eligible patients, 261 (49%) were defined as having inadequate blood pressure control at the end of the study period. No significant associations were discovered with sex, age, deprivation score and comorbidity. In those patients with inadequate control, 30% had no modifications to their drug treatment during the study period. Blood pressure control at the end of the study period was not associated with number of antihypertensive drugs taken or number of antihypertensive drug modifications. The mean number of clinician contacts was 11 (standard deviation = 8), and mean continuity in primary care was high, although this was not associated with improved blood pressure control. A higher proportion of hypertension-related consultations were associated with increased odds of having inadequate blood pressure control. CONCLUSION: Achieving adequate blood pressure control continues to represent a substantial health problem in a significant proportion of the hypertensive population. Patient, physician and organisational elements play a role in ensuring effective delivery of hypertension care in the community. 相似文献
22.
23.
M J Buxton S D Sullivan L F Andersson C J Lamm B Liljas W W Busse S Pedersen K B Weiss 《The European respiratory journal》2004,24(4):568-574
Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention. 相似文献
24.
25.
Antiserum raised to a factor elaborated by a lymphoblastoid cell line derived from the peripheral blood cells of an HLA-B27 positive patient with ankylosing spondylitis specifically lyses the B27 positive, but not the B27 negative, cells of ankylosing spondylitis patients. The cells of B27 positive and B27 negative normal controls are not lysed. This serum has similar specificity to antisera against cross-reactive bacteria. 相似文献
26.
27.
Margaret Sullivan Pepe Ziding Feng Gary Longton Joseph Koopmeiners 《Statistics in medicine》2009,28(5):762-779
Development of a disease screening biomarker involves several phases. In phase 2 its sensitivity and specificity is compared with established thresholds for minimally acceptable performance. Since we anticipate that most candidate markers will not prove to be useful and availability of specimens and funding is limited, early termination of a study is appropriate, if accumulating data indicate that the marker is inadequate. Yet, for markers that complete phase 2, we seek estimates of sensitivity and specificity to proceed with the design of subsequent phase 3 studies. We suggest early stopping criteria and estimation procedures that adjust for bias caused by the early termination option. An important aspect of our approach is to focus on properties of estimates conditional on reaching full study enrollment. We propose the conditional‐UMVUE and contrast it with other estimates, including naïve estimators, the well‐studied unconditional‐UMVUE and the mean and median Whitehead‐adjusted estimators. The conditional‐UMVUE appears to be a very good choice. Copyright © 2008 John Wiley & Sons, Ltd. 相似文献
28.
29.
Nathan J Koewler Katie T Freeman Ryan J Buus Monica B Herrera Juan M Jimenez-Andrade Joseph R Ghilardi Christopher M Peters Lucy J Sullivan Michael A Kuskowski Jack L Lewis Patrick W Mantyh 《Journal of bone and mineral research》2007,22(11):1732-1742
A closed femur fracture pain model was developed in the C57BL/6J mouse. One day after fracture, a monoclonal antibody raised against nerve growth factor (anti-NGF) was delivered intraperitoneally and resulted in a reduction in fracture pain-related behaviors of approximately 50%. Anti-NGF therapy did not interfere with bone healing as assessed by mechanical testing and histomorphometric analysis. INTRODUCTION: Current therapies to treat skeletal fracture pain are limited. This is because of the side effect profile of available analgesics and the scarcity of animal models that can be used to understand the mechanisms that drive this pain. Whereas previous studies have shown that mineralized bone, marrow, and periosteum are innervated by sensory and sympathetic fibers, it is not understood how skeletal pain is generated and maintained even in common conditions such as osteoarthritis, low back pain, or fracture. MATERIALS AND METHODS: In this study, we characterized the pain-related behaviors after a closed femur fracture in the C57BL/6J mouse. Additionally, we assessed the effect of a monoclonal antibody that binds to and sequesters nerve growth factor (anti-NGF) on pain-related behaviors and bone healing (mechanical properties and histomorphometric analysis) after fracture. RESULTS: Administration of anti-NGF therapy (10 mg/kg, days 1, 6, and 11 after fracture) resulted in a reduction of fracture pain-related behaviors of approximately 50%. Attenuation of fracture pain was evident as early as 24 h after the initial dosing and remained efficacious throughout the course of fracture pain. Anti-NGF therapy did not modify biomechanical properties of the femur or histomorphometric indices of bone healing. CONCLUSIONS: These findings suggest that therapies that target NGF or its cognate receptor(s) may be effective in attenuating nonmalignant fracture pain without interfering with bone healing. 相似文献